Activité physique et asthme sévère : résultats de l’étude FASE-CPHG

Coëtmeur, D.; Parrat, Éric; Nocent-Ejnaini, C.; Mangiapan, G.; Prudhomme, A.; Oster, Jean-Philippe; Vecchi, Corinne Appere de; Maurer, C.; Debieuvre, D.; Portel, L.

doi:10.1016/j.rmr.2019.12.004

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its secondary objectives were to compare data from patients with severe eosinophilic and non-eosinophilic asthma and describe the profile of patients with severe non-eosinophilic asthma according to their allergic profile. [13][14][15] Data from 1502 adult (>18 years) patients with severe asthma were collected from May 2016 to June 2017 in France by 104 respiratory physicians in non-academic hospitals. All patients received information about the study and gave their informed consent before being included in the FASE-CPHG study.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study

Portel¹,

Fabry-Vendrand²,

Texier³

et al. 2023

JAA

View full text Add to dashboard Cite

Purpose Data on severe non-eosinophilic asthma are scarce. Moreover, as compared with eosinophilic asthma, non-eosinophilic asthma less frequently benefits from the latest therapeutic advances. This study aimed to highlight differences between non-eosinophilic and eosinophilic asthma as they may help the development of new therapeutic agents. Patients and Methods Data from 1075 adult patients with severe asthma (GINA treatment: 4/5) collected during the cross-sectional non-interventional FASE-CPHG study were analyzed. Two groups of patients (EOS-/EOS+) were constituted based on blood eosinophil counts (cutoff value: 300 G/l). Characteristics of EOS- (N = 500) and EOS+ (N = 575) patients were described; EOS- patients were also described according to their allergic profile based on skin allergy or allergen-specific immunoglobulin E (IgE) assays (cutoff value: 150 IU/mL). Results Percentages of patients with obesity (29%), allergen sensitization (57%), or ≥2 annual exacerbations in the last 12 months (68%) were similar in both groups. As compared with EOS+ patients, EOS- patients less frequently reported chronic rhinitis (41.1% vs 50.5%, p < 0.01) or nasal polyposis (13.6% vs 27.5%, p < 0.01), and more frequently reported GERD (45.2% vs 37.1%, p < 0.01), anxiety (45.5% vs 38.1%, p = 0.01), or depression (18.3% vs 13.3%, p = 0.02). EOS- patients had lower serum total IgE levels (median: 158 vs 319 IU/mL, p < 0.01) and were less frequently treated with long-term oral corticosteroid therapy (16.0% vs 23.7%; p < 0.01). Their asthma was more frequently uncontrolled (48% vs 40%, p < 0.01). Similar results were found with a cutoff value for blood eosinophil counts at 150 G/l. EOS- patients with allergic profile less frequently reported high serum IgE levels (35.6% vs 57.9%, p < 0.01). EOS- and EOS+ patients treated with long-term oral corticosteroids had similar profiles. Conclusion In our patients with severe asthma, EOS- asthma was approximately as frequent as EOS+ asthma; EOS- asthma was frequently poorly controlled or uncontrolled, confirming the need for a better management. Allergy did not appear to worsen clinical profile.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Further details may be found in previous published articles. [13][14][15] Current analyses were performed using data that were deidentified.…”

Section: Methodsmentioning

confidence: 99%

Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study

Portel¹,

Fabry-Vendrand²,

Texier³

et al. 2023

JAA

View full text Add to dashboard Cite

show abstract

“…Our society encourages people to take part in sports, which helps to reduce the incidences of chronic diseases and allows patients with these diseases to maintain a better quality of life. Five to ten minutes of exercise a day could reduce all-cause mortality by 30% [ 1 , 2 , 3 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It

Vertadier

Trzépizur

Faure

2022

Sports

View full text Add to dashboard Cite

The use of short-acting beta-2 agonists (SABAs) is more common in elite athletes than in the general population, especially in endurance sports. The World Anti-Doping Code places some restrictions on prescribing inhaled β2-agonists. These drugs are used in respiratory diseases (such as asthma) that might reduce athletes’ performances. Recently, studies based on the results of the Olympic Games revealed that athletes with confirmed asthma/airway hyperresponsiveness (AHR) or exercise-induced bronchoconstriction (EIB) outperformed their non-asthmatic rivals. This overuse of SABA by high-level athletes, therefore, raises some questions, and many explanatory hypotheses are proposed. Asthma and EIB have a high prevalence in elite athletes, especially within endurance sports. It appears that many years of intensive endurance training can provoke airway injury, EIB, and asthma in athletes without any past history of respiratory diseases. Some sports lead to a higher risk of asthma than others due to the hyperventilation required over long periods of time and/or the high environmental exposure while performing the sport (for example swimming and the associated chlorine exposure). Inhaled corticosteroids (ICS) have a low efficacy in the treatment of asthma and EIB in elite athletes, leading to a much greater use of SABAs. A significant proportion of these high-level athletes suffer from non-allergic asthma, involving the th1-th17 pathway.

show abstract

Phenotyping to Target Obstructive Sleep Apnoea Syndrom (OSAS) in adults patients with severe asthma

Portel

Parrat

Nocent-Ejnaini

et al. 2022

Respiratory Medicine and Research

View full text Add to dashboard Cite

Activité physique et asthme sévère : résultats de l’étude FASE-CPHG

Cited by 4 publications

References 22 publications

Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study

Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study

Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It

Phenotyping to Target Obstructive Sleep Apnoea Syndrom (OSAS) in adults patients with severe asthma

Contact Info

Product

Resources

About